| Trial ID: | L0411 |
| Source ID: | NCT04550481
|
| Associated Drug: |
Lisinopril
|
| Title: |
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD): Relief-NAFLD
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Hepatocellular Carcinoma;Nonalcoholic Steatohepatitis
|
| Interventions: |
Drug: Lisinopril;Other: Questionnaire Administration
|
| Outcome Measures: |
Change in PRO-C3 valuesChange in PC3X (cross-linked multimeric PRO-C3);Change in steatosis;Change in steatosis;Change liver stiffness;Change liver stiffness;Change in non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS);Change in Fibrosis-4 score;Change in inflammatory markers (caspase cleaved cytokeratin 18, NF-kappaB, TGF-beta, TNF-alpha, IL6 and IL8)
|
| Sponsor/Collaborators: |
National Cancer Institute (NCI)
|
| Gender: |
All
|
| Age: |
18 Yearsnan
|
| Phases: |
Phase 2
|
| Enrollment: |
45
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label).
|
| Start Date: |
15/09/2020
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
21 February 2022
|
| Locations: |
United States
|
| URL: |
https://clinicaltrials.gov/show/NCT04550481
|
